CSE PREV
LAST 0.58
CHANGE 0.08
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.58
CHANGE: 0.08
OTC: PRVCF
FSE: 18H
Download as PDF  

Intention to Apply for Listing on the Canadian Securities Exchange

Vancouver, British Columbia, June 27, 2016 - PreveCeutical Medical Inc. ("PreveCeutical", or the "Company"), a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers, is pleased to announce that it intends to apply to the Canadian Securities Exchange (“CSE”) for the listing of its Class A common shares (“Shares”). The listing of the Shares will be subject to satisfactory review of the CSE of the Company’s listing application and the Company’s compliance with all applicable CSE policies and applicable corporate and securities laws. As of this date, no application to the CSE has been made and the Company intends to make its initial application to the CSE in July 2016. If you are interested in the future of Health Care - put us on your watch list.

PreveCeutical intends to build its growth and business on the following trends and hopes its intended listing will enable it to realize its growth strategy:

  1. Focus on Preventive Medicine.
    As information from electronic medical records becomes available in the cloud, health care tasks are moving online, and the digitalization of diagnoses has implications for predictive and preventive medicine. For example, when patients register slight increases in temperature through the use of wearable technologies, medical practitioners can detect early symptoms of potential viral infection, allowing them to implement care solutions to minimize symptomology and illness duration. (1) The Company intends for its preventative medicine product offering to complement such trend.
  2. Focus on natural treatments, cures and remedies.
    There is a consumer driven market emerging for “alternative” treatments. Western medicine and big pharma are facing a market that demands access to much more information and are examining natural products and treatments that have not been included in the Western approach to medicine. A good example of this is the growing interest being driven by millennials in vitamins and supplements, including the huge interest in cannabis, holistic medicines and other traditional remedies. 1)Chinese Alternative Health Practitioners recognized Scorpion Venoms effectiveness centuries ago. 2)Now, scientists have devised a method for targeting venom proteins specifically to malignant cells while sparing healthy ones, which reduces or eliminates side effects that the toxins would otherwise cause. As such, increase in consumer focus on natural treatments, cures and remedies may help the Company better market its Blue Scorpion Venom.
  3. Personalization of Healthcare.
    The Internet has the potential to enable the connection of devices that can support predictive medicine and products by linking a patient’s wellness goals to their lifestyle, and PreveCeutical believes that this may lead into opportunities for providing personalized healthcare and such provision moving from being a luxury to a necessity in competitive healthcare markets.(3)

1) Sciencedaily.com at https://www.sciencedaily.com/releases/2010/02/100216163341.htm (2)“American Chemical Society” acs.org at https://www.acs.org/content/acs/en/pressroom/newsreleases/2014/august/venom-gets-good-buzz-as-potential-cancer-fighter-video.html (3) Certain trends mentioned are from an article by Fortune.com at http://fortune.com/2015/02/26/5-remarkable-facts-about-the-future-of-health-care/

If you would like to be regularly updated on Nature, Science, Technologies and Treatment Trends for Healthcare in the 21st Century, contact us at the following email and we will add you to our newsletter: info@preveceutical.com.

About PreveCeutical

PreveCeutical is health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers and currently offers Blue Scorpion Venom derived from scorpion venom. For more information about PreveCeutical, please visit www.preveceutical.com, follow us on Twitter: https://twitter.com/preveceuticals, or on Facebook: www.facebook.com/Preveceutical.

On Behalf of the Board,

"Stephen Van Deventer"
President & CEO

CAUTIONARY DISCLAIMER STATEMENT

The Company is not currently listed on the CSE or any stock exchange or quotation system. No stock exchange or securities regulatory authorized has reviewed or accepts responsibility for the adequacy or accuracy of the content of this news release. This news release is for information purposes only and should not be construed as a securities offering by the Company.

This news release contains forward-looking statements, including without limitation, regarding the future operations of the Company and the healthcare industry. Forward-looking statements address future events and conditions and therefore involve inherent risks, uncertainties and assumptions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future or future trends. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “will”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. There can be no assurance that such forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the listing conditions of the CSE or the management’s decision to abandon such listing for any reason.

Actual results may differ materially from those currently anticipated in such statements and the Company undertakes no obligation to update such statements, except as required by law. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. In particular, there is no guarantee that the Company will be able to list its Shares on the CSE, no guarantee that the trends identified in this news release will benefit the Company, and that Blue Scorpion Venom will effectively treat or cure or prevent any diseases. Accordingly actual results may differ materially from those currently anticipated in such statements.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. The reader is cautioned not to place undue reliance on any forward-looking information. The Company has made numerous assumptions regarding, among other things: the effectiveness of its products; the demand for its products and the stability of economic and market conditions. Readers are cautioned that all forward-looking statements involve risks and uncertainties, including: that the Company may lose or abandon or may fail to receive necessary licenses and permits; labour disputes affecting the Company; the Company may not receive the necessary regulatory approvals for its products or the intended listing; the increase in cost estimates and the potential for unexpected costs and expenses; worsening of general economic and market conditions; market shifts may require a change in strategic focus; the Company may not be able to raise additional funds when necessary; litigation affecting the Company; and competition. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability or lack of availability of suitable capital and financing or capital and financing in general for the Company, and general economic, market or business conditions, consumer sentiment towards the Company’s products, competition, the failure of counterparties to perform their contractual obligations, and fees charged by service providers.

All forward-looking statements concerning the Company's future plans and operations, including management's assessment of the Company's operational expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates or projections. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Sign up for the latest news and updates